Skip to main content
Top
Published in: Journal of Public Health 6/2012

01-12-2012 | Original Article

What drives the costs of heart failure care in Germany? A health services cost analysis

Authors: Frank Peters-Klimm, Anna Halmer, Steffen Flessa, Joachim Szecsenyi, Dominik Ose

Published in: Journal of Public Health | Issue 6/2012

Login to get access

Abstract

Aims

Heart failure (HF) represents an increasing burden on health-care systems because of the aging population. The aim of this study was to explore its costs of care in Germany from the payer perspective and to identify the main drivers.

Subjects and methods

As part of a trial, primary care physicians (PCPs) enrolled eligible patients and documented actual clinical and 12-month retrospective ambulatory health-care utilisation data related to HF [PCP and cardiologist contacts, and cardiovascular (CV) medication] and provided the doctors’ reports of hospitalisations during 2004 and 2005, enabling the collection and calculation of costs. Furthermore, each hospitalisation was classified according to the cause of admission into HF, CV or other hospitalisation.

Results

Thirty-seven physicians enrolled 168 patients with complete data of 159 patients (95 %). Patients (mean age 68 ± 10 years, 73 % male, 47 % ischaemic aetiology) had ascertained systolic HF (mean ejection fraction 33 ± 7 %) with NYHA class II/III in 53/45 %. Mean (SD; median) annual costs of 96 hospitalisations, CV medication, and 337 cardiologist and 3,037 PCP practice contacts were 3,545 (8,065; 0), 854 (835; 638), 117 (105; 106) and 269 (190; 233) euros, respectively, totalling 4,792 (8249;1341) euros. Fourteen per cent of all patients incurred 50 % of total costs. Twenty-five HF, 49 CV and 22 other hospitalisations incurred 13, 73 and 14 % of hospital care costs, respectively.

Conclusions

These secondary outcome data might indicate a trend that neither HF ambulatory care nor hospitalisation but rather interventional cardiology is the main cost driver. Planning interventions aimed at reduced hospitalisation and costs should include further clarification of the mechanisms of CV hospitalisation and reimbursement.
Appendix
Available only for authorised users
Literature
go back to reference Al Khatib SM, Hellkamp A, Curtis J et al (2011) Non-evidence-based ICD implantations in the United States. JAMA 305:43–49PubMedCrossRef Al Khatib SM, Hellkamp A, Curtis J et al (2011) Non-evidence-based ICD implantations in the United States. JAMA 305:43–49PubMedCrossRef
go back to reference Clabaugh G, Ward MM (2008) Cost-of-illness studies in the United States: a systematic review of methodologies used for direct cost. Value Health 11:13–21PubMedCrossRef Clabaugh G, Ward MM (2008) Cost-of-illness studies in the United States: a systematic review of methodologies used for direct cost. Value Health 11:13–21PubMedCrossRef
go back to reference Dickstein K, Cohen-Solal A, Filippatos G et al (2008) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 10:933–989PubMedCrossRef Dickstein K, Cohen-Solal A, Filippatos G et al (2008) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 10:933–989PubMedCrossRef
go back to reference Graf von der Schulenburg JM, Greiner W, Jost F et al (2008) German recommendations on health economic evaluation: third and updated version of the Hanover Consensus. Value Health 11:539–544PubMedCrossRef Graf von der Schulenburg JM, Greiner W, Jost F et al (2008) German recommendations on health economic evaluation: third and updated version of the Hanover Consensus. Value Health 11:539–544PubMedCrossRef
go back to reference Jaarsma T, van der Wal MHL, Lesman-Leegte I et al (2008) Effect of moderate or intensive disease management program on outcome in patients with heart failure: coordinating study evaluating outcomes of advising and counseling in heart failure (COACH). Arch Intern Med 168:316–324PubMedCrossRef Jaarsma T, van der Wal MHL, Lesman-Leegte I et al (2008) Effect of moderate or intensive disease management program on outcome in patients with heart failure: coordinating study evaluating outcomes of advising and counseling in heart failure (COACH). Arch Intern Med 168:316–324PubMedCrossRef
go back to reference Krauth C, Hessel F, Hansmeier T, Wasem J, Seitz R, Schweikert B (2005) Empirical standard costs for health economic evaluation in Germany—a proposal by the working group methods in health economic evaluation. Gesundheitswesen 67:736–746PubMedCrossRef Krauth C, Hessel F, Hansmeier T, Wasem J, Seitz R, Schweikert B (2005) Empirical standard costs for health economic evaluation in Germany—a proposal by the working group methods in health economic evaluation. Gesundheitswesen 67:736–746PubMedCrossRef
go back to reference McMurray JJ, Stewart S (2000) Epidemiology, aetiology, and prognosis of heart failure. Heart 83:596–602PubMedCrossRef McMurray JJ, Stewart S (2000) Epidemiology, aetiology, and prognosis of heart failure. Heart 83:596–602PubMedCrossRef
go back to reference Neumann T, Biermann J, Erbel R et al (2009) Heart failure: the commonest reason for hospital admission in Germany: medical and economic perspectives. Dtsch Arztebl Int 106:269–275PubMed Neumann T, Biermann J, Erbel R et al (2009) Heart failure: the commonest reason for hospital admission in Germany: medical and economic perspectives. Dtsch Arztebl Int 106:269–275PubMed
go back to reference Peters-Klimm F, Muller-Tasch T, Remppis A et al (2008) Improved guideline adherence to pharmacotherapy of chronic systolic heart failure in general practice—results from a cluster-randomized controlled trial of implementation of a clinical practice guideline. J Eval Clin Pract 14:823–829PubMedCrossRef Peters-Klimm F, Muller-Tasch T, Remppis A et al (2008) Improved guideline adherence to pharmacotherapy of chronic systolic heart failure in general practice—results from a cluster-randomized controlled trial of implementation of a clinical practice guideline. J Eval Clin Pract 14:823–829PubMedCrossRef
go back to reference Peters-Klimm F, Campbell S, Müller-Tasch T et al (2009) Primary care-based multifaceted, interdisciplinary medical educational intervention for patients with systolic heart failure: lessons learned from a cluster randomised controlled trial. Trials 10:68PubMedCrossRef Peters-Klimm F, Campbell S, Müller-Tasch T et al (2009) Primary care-based multifaceted, interdisciplinary medical educational intervention for patients with systolic heart failure: lessons learned from a cluster randomised controlled trial. Trials 10:68PubMedCrossRef
go back to reference Peters-Klimm F, Laux G, Campbell S et al (2012) Physician and patient predictors of evidence-based prescribing in heart failure: a multilevel study. PLoS One 7:e31082PubMedCrossRef Peters-Klimm F, Laux G, Campbell S et al (2012) Physician and patient predictors of evidence-based prescribing in heart failure: a multilevel study. PLoS One 7:e31082PubMedCrossRef
go back to reference Rickham PP (1964) Human experimentation. Code of ethics of the World Medical Association. Declaration of Helsinki. Br Med J 2:177PubMedCrossRef Rickham PP (1964) Human experimentation. Code of ethics of the World Medical Association. Declaration of Helsinki. Br Med J 2:177PubMedCrossRef
go back to reference Solomon SD, Dobson J, Pocock S et al (2007) Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation 116:1482–1487PubMedCrossRef Solomon SD, Dobson J, Pocock S et al (2007) Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation 116:1482–1487PubMedCrossRef
go back to reference Taylor S, Bestall J, Cotter S et al. (2005) Clinical service organisation for heart failure. Cochrane Database Syst Rev: CD002752 Taylor S, Bestall J, Cotter S et al. (2005) Clinical service organisation for heart failure. Cochrane Database Syst Rev: CD002752
go back to reference Young JB, Dunlap ME, Pfeffer MA et al (2004) Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation 110:2618–2626PubMedCrossRef Young JB, Dunlap ME, Pfeffer MA et al (2004) Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation 110:2618–2626PubMedCrossRef
go back to reference Zugck C, Muller A, Helms TM et al (2010) Health economic impact of heart failure: An analysis of the nationwide German database. Dtsch Med Wochenschr 135:633–638PubMedCrossRef Zugck C, Muller A, Helms TM et al (2010) Health economic impact of heart failure: An analysis of the nationwide German database. Dtsch Med Wochenschr 135:633–638PubMedCrossRef
Metadata
Title
What drives the costs of heart failure care in Germany? A health services cost analysis
Authors
Frank Peters-Klimm
Anna Halmer
Steffen Flessa
Joachim Szecsenyi
Dominik Ose
Publication date
01-12-2012
Publisher
Springer-Verlag
Published in
Journal of Public Health / Issue 6/2012
Print ISSN: 2198-1833
Electronic ISSN: 1613-2238
DOI
https://doi.org/10.1007/s10389-012-0501-3

Other articles of this Issue 6/2012

Journal of Public Health 6/2012 Go to the issue